Literature DB >> 22090713

Characterization of cryptic rearrangements, deletion, complex variants of PML, RARA in acute promyelocytic leukemia.

Pratibha Kadam Amare1, Chanda Baisane, Reena Nair, Hari Menon, Shripad Banavali, Sharayu Kabre, Sumit Gujral, P Subramaniam.   

Abstract

Acute promyelocytic leukemia (APL) is characterized by a reciprocal translocation t(15;17)(q22;q21) leading to the disruption of Promyelocytic leukemia (PML) and Retionic Acid Receptor Alpha (RARA) followed by reciprocal PML-RARA fusion in 90% of the cases. Fluorescence in situ hybridization (FISH) has overcome the hurdles of unavailability of abnormal and/or lack of metaphase cells, and detection of cryptic, submicroscopic rearrangements. In the present study, besides diagnostic approach we sought to analyze these cases for identification and characterization of cryptic rearrangements, deletion variants and unknown RARA translocation variants by application of D-FISH and RARA break-apart probe strategy on interphase and metaphase cells in a large series of 200 cases of APL. Forty cases (20%) had atypical PML-RARA and/or RARA variants. D-FISH with PML/RARA probe helped identification of RARA insertion to PML. By application of D-FISH on metaphase cells, we documented that translocation of 15 to 17 leads to 17q deletion which results in loss of reciprocal fusion and/or residual RARA on der(17). Among the complex variants of t(15;17), PML-RARA fusion followed by residual RARA insertion closed to PML-RARA on der(15) was unique and unusual. FISH with break-apart RARA probe on metaphase cells was found to be a very efficient strategy to detect unknown RARA variant translocations like t(11;17)(q23;q21), t(11;17)(q13;q21) and t(2;17)(p21;q21). These findings proved that D-FISH and break-apart probe strategy has potential to detect primary as well as secondary additional aberrations of PML, RARA and other additional loci. The long-term clinical follow-up is essential to evaluate the clinical importance of these findings.

Entities:  

Keywords:  17q deletion; APL; D-FISH; PML-RARA; RARA variant

Year:  2011        PMID: 22090713      PMCID: PMC3214318          DOI: 10.4103/0971-6866.86174

Source DB:  PubMed          Journal:  Indian J Hum Genet        ISSN: 1998-362X


Introduction

Acute promyelocytic leukemia (APL) is characterized by reciprocal translocation t(15;17)(q22;q21) leading to the disruption of PML and RARA followed by a reciprocal PMLRARA fusion in 90% of the cases.[1-7] Molecular cytogenetics like interphase fluorescence in situ hybridization (FISH) has overcome the hurdles of unavailability of abnormal and/or lack of metaphase cells, detection of cryptic, submicroscopic rearrangements due to insertion events, identification of complex variants as well as RARA translocation variants that has diagnostic utility in the diagnosis as well as management of disease.[68-12] Besides diagnostic approach, we sought to analyze these cases for identification and characterization of cryptic rearrangements, deletion variants and unknown RARA translocation variants by application of D-FISH and RARA break-apart probe strategy on metaphase cells in APL at diagnosis.

Materials and Methods

The present study included 200 APL patients who belonged to the age group 1–70 years. Patients who were diagnosed by standard morphology criteria and immunophenotype criteria, between January 2005 and December 2010, were enrolled in this study. Molecular Cytogenetics-Fluorescence-in-situ hybridization (FISH) is part of the routine diagnostic criteria and also for monitoring treatment for evaluation of cytogenetic remission. Cytogenetic preparation was carried out on bone marrow aspirate and occasionally on peripheral blood. Interphase and metaphase D-FISH were performed using LSI dual color dual fusion PML/RARA and dual color break-apart rearrangement RARA probe (Vysis Abbott molecular, Delkenheim, Germany) as per manufacturer's protocol and instructions. For every batch of probe, studies were carried out on 10 specimens which included peripheral blood from normal individuals and marrow aspirations from Bone Marrow Transplantation (BMT) donors to check the sensitivity of probe. We scored 500 interphase nuclei and 10–20 metaphase cells in each normal specimen. In patients, a minimum of 100–200 and 5–15 metaphase cells were scored for evaluation of FISH signals by two observers in a blinded fashion. For PML/RARA probe, presence of two separated red (R) and two green (G) signals in non-overlapping distinct nuclei were considered as PMLRARA negative and 1R, 1G and 2 co-localized/fusion red/green signals were considered as PMLRARA dual fusion positive. For RARA break-apart probe, distinct, well-separated red and green signals in non-overlapping nuclei were considered as RARA gene break/split. Deviation in signal pattern of PMLRARA in interphase cells was evaluated on metaphase cells whenever available. Deletion, complex variants and RARA translocation variants were additionally confirmed on inverted 4’, 6-diamidino-2-phenylindole (DAPI) image. Whenever required, CEP probe/s were used to confirm suspected chromosome.

Results and Discussion

Molecular characterization and interpretation of PMLRARA fusion positive cases by D-FISH using PML/RARA probe is given in Table 1 and Figure 1.
Table 1

Signal pattern and incidence of standard PML–RARA, cryptic/masked PML–RARA, deletion variants and RARA variant translocations by D-FISH with PML/RARA probe and RARA break-apart rearrangement probe, respectively

Figure 1

(a) D-FISH with LSI PML–RARA on metaphase cell shows normal PML allele (red signal), normal RARA allele (green signal) reciprocal PML–RARA fusion on der(15) (yellow signal) and der(17) (yellow signal). (b) LSI PML–RARA on metaphase cell shows PML–RARA fusion on der(15) (yellow signal) and residual PML on der(17) (red signal) (white arrow). (c) LSI PML–RARA on metaphase cell shows PML–RARA fusion on der(15) (yellow signal), also shows Aqua CEP 17 normal and der(17) (white arrow). (d) LSI PML–RARA on metaphase cell shows PML–RARA fusion on der(15) (yellow signal) and duplication of PML–RARA on i(17q) (yellow signals). (e) LSI PML–RARA on metaphase cell shows PML–RARA fusion on der (15) (yellow signal), residual RARA on der(15) (green signal) next to PML–RARA fusion and residual PML signal on der(17) (red signal) (white arrow). (f) Dual color RARA break-apart probe on metaphase cell shows normal RARA allele on 17 (yellow signal), residual RARA on der(17) (red signal) and residual RARA on der(11) at band 11q23 (green signal). (g) Dual color RARA break-apart probe on metaphase cell shows normal RARA allele on 17 (yellow signal), residual RARA on der17 (red signal) and residual RARA on der(11) at band 11q13 (green signal). (h) Dual color RARA break-apart probe on metaphase cell shows normal RARA allele on 17 (yellow signal), residual RARA on der(17) (red signal) and residual RARA on der(2) at band 2p21 (green signal)

Signal pattern and incidence of standard PMLRARA, cryptic/masked PMLRARA, deletion variants and RARA variant translocations by D-FISH with PML/RARA probe and RARA break-apart rearrangement probe, respectively (a) D-FISH with LSI PMLRARA on metaphase cell shows normal PML allele (red signal), normal RARA allele (green signal) reciprocal PMLRARA fusion on der(15) (yellow signal) and der(17) (yellow signal). (b) LSI PMLRARA on metaphase cell shows PMLRARA fusion on der(15) (yellow signal) and residual PML on der(17) (red signal) (white arrow). (c) LSI PMLRARA on metaphase cell shows PMLRARA fusion on der(15) (yellow signal), also shows Aqua CEP 17 normal and der(17) (white arrow). (d) LSI PMLRARA on metaphase cell shows PMLRARA fusion on der(15) (yellow signal) and duplication of PMLRARA on i(17q) (yellow signals). (e) LSI PMLRARA on metaphase cell shows PMLRARA fusion on der (15) (yellow signal), residual RARA on der(15) (green signal) next to PMLRARA fusion and residual PML signal on der(17) (red signal) (white arrow). (f) Dual color RARA break-apart probe on metaphase cell shows normal RARA allele on 17 (yellow signal), residual RARA on der(17) (red signal) and residual RARA on der(11) at band 11q23 (green signal). (g) Dual color RARA break-apart probe on metaphase cell shows normal RARA allele on 17 (yellow signal), residual RARA on der17 (red signal) and residual RARA on der(11) at band 11q13 (green signal). (h) Dual color RARA break-apart probe on metaphase cell shows normal RARA allele on 17 (yellow signal), residual RARA on der(17) (red signal) and residual RARA on der(2) at band 2p21 (green signal) D-FISH using LSI PML/RARA probe confirmed standard reciprocal PMLRARA in interphase and metaphase cells in 160 patients [Figure 1a]. The frequency for false-positive interphase nuclei in normal controls for 1R 1G 2F, 2R 1G 1F, 1R 2G 1F, 1R 1G 3F, and 2R 2G 1F was 0.2%, 0.4%, 0.4%, 0.2%, and 0.2%, respectively. The specimens with 1R 1G 2F, 2R 1G 1F, 1R 2G 1F, 1R 1G 3F, and 2R 2G 1F were considered positive if the value exceeded >1%. The specimens with 1R 1G 1F were considered positive if the value exceeded >5%. The PMLRARA positive or RARA split positive cells were in the range of 50–90%. In 12 out of 40 patients with variant PMLRARA pattern, proper metaphase cells were not available for characterization either due to lack of metaphase cells or presence of metaphase cells of poor morphology or presence of normal dividing cells. In 9 out of 12 cases with 2R 1G 1F signal pattern, 17q21→qter region with residual RARA translocated to 15q22 followed by fusion PMLRARA (yellow signal). Presence of residual PML on der(17) was due to reciprocal translocation; however, derivative 17 showed lack of reciprocal fusion due to loss of 17q deletion which was confirmed by inverted DAPI image [Figure 1b, Table 1]. In six out of nine cases with 1R 1G 1F signal pattern in metaphase cells, there was a lack of reciprocal fusion on der(17). An inverted DAPI image revealed normal appearing chromosome 17 in four cases which indicated interstitial insertion of whole RARA into PML on der(15). This is consistent with masked PMLRARA, a common event known to occur in APL with t(15;17) negative cases by conventional karyotyping.[9101314] In three cases, der(17) appeared to be small [Figure 1c]. These findings and documented evidence of the presence of residual PML on der(17) in cases with 2R 1G 1F [Figure 1b] support the fact that loss of DNA at 17q21 region occurs in a small group of APL patients. The poor morphology of metaphase cells probably masks the abnormal 17 by conventional cytogenetics as discussed by others.[715] The signal pattern 1R 2G 1F observed in three cases was detected on interphase cells due to unavailability of abnormal metaphase cells. The nonreciprocal fusion pattern with the presence of residual RARA probably suggests deletion of 15qter region. Loss of DNA material on 9q is very common in Chronic Myeloid Leukemia (CML) cases.[1617] We have also detected nonreciprocal BCR-ABL with 9q deletion/res ABL deletion/res BCR deletion in a large CML series of 2000 cases (our unpublished data). Our vast experience in various hematological malignancies like Acute Lymphoblastic Leukemia (ALL)[18-20] in lymphoma[21] which support the notion that genomic deletions followed by translocations are common events in hematological malignancies. Metaphase analysis of cases with 1R 1G 3F helped identification of duplication of PMLRARA on both arms of 17q as a result of i(17q) in three cases [Figure 1d]. Additional copies of PMLRARA due to i(17q) or duplication of der(17) are not uncommon events in APL.[722] An i(17q) with duplication of PMLRARA is similar to Ph duplication as a result of either i(ph) or two separate copies of Ph chromosome in Chronic Myeloid Leukemia – Accelerated Phase (CML-AP) or CML-BP.[623] D-FISH strategy was found to be very efficient to detect complex variant translocation of PMLRARA. We identified six cases with 2R 2G 1F signal pattern. We could characterize one variant with PMLRARA on der(15) at locus 15q22 as result of translocation and additionally insertion of residual RARA at locus 15q15 next to PMLRARA and residual RARA on der(17) [Figure 1e]. The overall signal pattern on metaphase cell was interpreted as two sequential events: first t(15;17): PMLRARA on der(15), followed by an insertion of residual RARA on der(15). Such atypical PML, RARA rearrangement was very unusual, and not reported before to our knowledge. The complex variants involving 15, 17 and a third chromosome have been reported.[111315] Review of literature on deletion variants or cryptic masked/complex variants of PMLRARA revealed very few reports. Studies of Thomas et al.(11) in 52 cases of APL showed 6% incidence. Our large series data revealed 14% incidence of deletion/complex variants of PMLRARA. Six cases with 2R 1G 2 dimG signal pattern revealed RARA translocation with partner chromosome other than 15 [Table 1]. Application of FISH with dual color RARA break-apart probe on interphase cells showed 1R 1G 1Y signal. The analysis of metaphase cells identified chromosome 11 as a partner chromosome in four cases. Inverted DAPI image helped in the identification of break point at band 11q23, a locus of PLZF in two cases [Figure 1f] and band 11q13, a locus of nuclear mitotic apparatus (NUMA) (two cases) [Figure 1g]. Among the variant RARA translocations, translocations involving 11q23 and 11q13 locus are frequent and found to show resistance to retinoid therapy.[24-26] Besides t(11;17(q13;q21) and t(11;17)(q23;q21), t(2;17) (p21;q21) was identified in our series [Figure 1h]. To our knowledge, t(2;17)(p21;q21) was not reported before in APL. The incidence of RARA variant translocations in our series of APL was 3% which is similar (1–2%) to those reported in other geographic areas.[5725] In conclusion, D-FISH strategy was found to be very efficient, sensitive and reliable approach in comparison with conventional cytogenetics in the diagnosis of APL. In the present large-scale study, it helped in the identification of cryptic rearrangements like insertion of RARA to PML. We also documented that translocation of 15 to 17 leads to 17q deletion which results in loss of reciprocal fusion and/or residual RARA on der(17). Apart from deletion variants, complex variant translocations of PMLRARA could also be detected by D-FISH interphase and metaphase approach. Among complex variants, t(15;17) followed by residual RARA insertion was unique and unusual. Combination of D-FISH and break-apart RARA probe proved its ability to detect unknown variant RARA translocations other than t(11;17) like t(11;17)(q23;q21), t(11;17)(q13;q21) and t(2;17)(p21;q21). The understanding of underlying biology will be able to focus upon the pathogenesis with respect to resistance to All-Trans-Retinoic-Acid (ATRA) therapy in APL. These findings proved that D-FISH and break-apart probe strategy have the potential to detect primary as well as secondary additional aberrations of PML and RARA and other additional loci. The long-term clinical follow-up is essential to evaluate the clinical importance of these findings. Also, additional large-scale studies are awaited to support the clinical and biological significance.
  24 in total

1.  New cytogenetic variant, insertion (15;17)(q22;q12q21), in an adolescent with acute promyelocytic leukemia.

Authors:  Raj Rolston; Karen E Weck; Jean M Tersak; Maureen E Sherer; Kathleen Cumbie; Sofia Shekhter-Levin
Journal:  Cancer Genet Cytogenet       Date:  2002-04-01

2.  Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia.

Authors:  R A Wells; C Catzavelos; S Kamel-Reid
Journal:  Nat Genet       Date:  1997-09       Impact factor: 38.330

3.  Submicroscopic insertion of RARalpha gene into chromosome 15 in two cases of acute promyelocytic leukemia.

Authors:  F Viguié; A Aboura; S Ramond; D Bouscary; M Baudard; C Chomienne; J P Marie
Journal:  Cancer Genet Cytogenet       Date:  2000-06

4.  Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.

Authors:  Alfonso Quintas-Cardama; Hagop Kantarjian; Moshe Talpaz; Susan O'Brien; Guillermo Garcia-Manero; Srdan Verstovsek; Mary Beth Rios; Kimberly Hayes; Armand Glassman; B Nebiyou Bekele; Xian Zhou; Jorge Cortes
Journal:  Blood       Date:  2004-11-30       Impact factor: 22.113

5.  Acute promyelocytic leukemia: a curable disease.

Authors:  F Lo Coco; C Nervi; G Avvisati; F Mandelli
Journal:  Leukemia       Date:  1998-12       Impact factor: 11.528

6.  All-trans-retinoic acid (ATRA): pediatric acute promyelocytic leukemia.

Authors:  A Bapna; R Nair; K S Tapan; C N Nair; P Kadam; B Gladstone; S H Advani
Journal:  Pediatr Hematol Oncol       Date:  1998 May-Jun       Impact factor: 1.969

7.  Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17).

Authors:  J D Licht; C Chomienne; A Goy; A Chen; A A Scott; D R Head; J L Michaux; Y Wu; A DeBlasio; W H Miller
Journal:  Blood       Date:  1995-02-15       Impact factor: 22.113

8.  Acute promyelocytic leukemia: all-trans retinoic acid (ATRA) along with chemotherapy is superior to ATRA alone.

Authors:  S H Advani; R Nair; A Bapna; B Gladstone; P Kadam; T K Saikia; P M Parekh; R Gopal; C N Nair
Journal:  Am J Hematol       Date:  1999-02       Impact factor: 10.047

9.  RUNX1 aberrations in ETV6/RUNX1-positive and ETV6/RUNX1-negative patients: its hemato-pathological and prognostic significance in a large cohort (619 cases) of ALL.

Authors:  Anurita Peter Pais; Pratibha S Amare Kadam; Gauri Chandrakant Raje; Shripad Banavali; Purvish Parikh; Purna Kurkure; Brijesh Arora; Sumit Gujral; S Ashok Kumar; Y Badrinath
Journal:  Pediatr Hematol Oncol       Date:  2008-09       Impact factor: 1.969

10.  Coexistence of ETV6/RUNX1 and MLL aberrations in B-cell precursor acute lymphoblastic leukemia discloses a small subclass of BCP-ALL.

Authors:  Pratibha S Amare Kadam; Gauri Chandrakant Raje; Anurita Peter Pais; Shripad Banavali
Journal:  Cancer Genet Cytogenet       Date:  2008-04-01
View more
  3 in total

1.  Construction of protein profile classification model and screening of proteomic signature of acute leukemia.

Authors:  Yun Xu; Jiacai Zhuo; Yonggang Duan; Benhang Shi; Xuhong Chen; Xiaoli Zhang; Liang Xiao; Jin Lou; Ruihong Huang; Qiongli Zhang; Xin Du; Ming Li; Daping Wang; Dunyun Shi
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

2.  Chromosomal aberrations in hematological malignancies: A guide to the identification of novel oncogenes.

Authors:  Babu Rao Vundinti; Kanjaksha Ghosh
Journal:  Indian J Hum Genet       Date:  2011-05

3.  Acute promyelocytic leukemia with a cryptic insertion of RARA into PML on chromosome 15 due to uniparental isodisomy: A case report.

Authors:  Anna Venci; Rita Mazza; Orietta Spinelli; Luciana Di Schiena; Daniela Bettio
Journal:  Oncol Lett       Date:  2017-04-03       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.